Kornimate/medical-research-clean huggingface dataset:
effect of high cocoa content chocolate on health in postmenopausal women.

Conditions: Postmenopausal Women

Summary: this is a randomized clinical trial aimed at postmenopausal women aged 50 to 64 years old selected in urban primary care centers of two centers (spain). its objective is to evaluate the effects of the additional intake of high cocoa content chocolate on blood pressure, vascular function, body composition, quality of life and cognitive performance.

* objective: to assess the effect at 6 months of the additional intake of 10 g/day of high cocoa content chocolate for 6 months on blood pressure, vascular function, body composition, quality of life and cognitive performance in postmenopausal women. * design and setting: a randomized clinical trial of two parallel groups. population: 140 postmenopausal women, 50 to 64 aged will be included, selected by consecutive sampling in two primary care centers. * measurements and intervention: vascular function (blood pressure, augmentation index and cardio-ankle vascular index), body composition and health-related quality of life will be evaluated. the intervention group will receive a daily supplement of high cocoa content chocolate for 6 months.

Eligibility criteria:
inclusion criteria: * women in postmenopausal period defined as 12 consecutive months of amenorrhea. exclusion criteria: * older than 65 years. * cardiovascular disease (acute myocardial infarction, stroke). * arterial hypertension on treatment. * diabetes mellitus. * dyslipidemia (total cholesterol \>250 mg/dl or in lipid-lowering therapy). * clinically demonstrable neurological and/or neuropsychological disorders. * hormone replacement therapy. * allergy and/or intolerance to cocoa or any of the components of the supplement. * hypocaloric diet. * any other circumstance that the investigators consider could interfere with the study procedures.

Keywords: cocoa vascular function body composition quality of life cognitive performance postmenopausal women
to demonstrate superiority of decitabine over azacitidine in subjects with intermediate- or high-risk mds.

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to compare the response of patients with intermediate or high risk myelodysplastic syndromes (mds) following treatment with decitabine or azacitidine.


Eligibility criteria:
inclusion criteria subjects who meet all of the following criteria may be included in the study: 1. must have a diagnosis of primary myelodysplastic syndromes (mds) of intermediate-1 transfusion dependent, intermediate-2, or high-risk \[defined by international prognostic scoring system (ipss) score of ≥0.5\] and recognized french-american-british (fab) classifications 2. male or female, 18 years of age or older with signed informed consent 3. adequate renal function 4. demonstrated normal liver function 5. female subjects of childbearing age must have negative pregnancy test within 1 week of study entry and agree to use adequate contraception for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received. 6. male subjects must agree to use adequate contraception for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received. exclusion criteria subjects who meet any of the following criteria will be excluded from participation in the study: 1. current use of radiotherapy for extramedullary disease for 2 weeks prior to entering study (permitted if \> 2 weeks from study entry and if recovered from toxic effects of therapy) 2. systemic fungal, bacterial, or viral infection which is not controlled (i.e., ongoing signs or symptoms of infection and without improvement despite appropriate treatment) 3. pregnancy or current lactation 4. significant concurrent disease, illness, or psychiatric disorder 5. treatment with an investigational agent 30 days prior to the first dose of decitabine or azacitidine

Keywords: mds myelodysplastic syndromes
sitting versus horizontal position on craniotomies

Conditions: Craniotomy; Brain Tumor

Summary: the main objectives of this study are comparison of the incidence of intraoperative air embolism and the extent of blood loss in patients undergoing posterior cranial fossa (pcf) and pineal region (pr) surgeries in sitting and horizontal position. additionally, the overall treatment outcome, neurological functional outcome, degree of tumor removal, clinical course in the postoperative period, and the patient satisfaction will be compared between the groups.

this was a prospective observational study to assess the effects of patient positioning during craniotomies on surgical outcomes. patients were distributed into 2 major groups based on the surgical position: sitting and horizontal. each group was further divided into subgroups based on the type and location of the lesion. to achieve the study goals, comparison of the 2 approaches in equivalent patient groups was performed, including comparable demographics, diagnoses, topographic location of the lesions, anesthetic approaches, and surgical experience. the operating surgeons decided patient positioning based on clinical judgment. type of anesthesia was defined by the anesthesiologist in charge of the patient however, it was maximally standardized for both sites. all the surgeries were performed by neurosurgeons with sufficient experience of sitting craniotomies.

Eligibility criteria:
inclusion criteria: * patients 18 - 75 years old undergoing open posterior cranial fossa and pineal region surgery and diagnosed with space-occupying or vascular lesions willing consent to participate in the study. exclusion criteria: * significant cardio-vascular comorbid conditions (cardiac insufficiency, recent infarction, advanced arterial hypertension) * advanced chronic respiratory comorbid conditions * uncorrected hypovolemia, anemia, hypoalbuminemia * de-compensated acid base and electrolyte disorders * anticoagulated patients and patients with coagulation disorders, deep venous thrombosis (history of deep vein thrombosis or clinically established) * preoperative evidence of spinal or peripheral nerve dysfunction that may interfere with patient positioning. * cervical myelopathy * cervical spine disorders (atlanto-occipital arthritis, previous fractures etc.)

Keywords: posterior fossa pineal region
a study by scintigraphy to evaluate the effect of exenatide on gastric emptying in subjects with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: as exenatide slows the rate at which materials leave the stomach, it is likely to alter the rate of intestinal absorption of oral drugs when administered within a certain timeframe relative to exenatide. in addition, the residence time within the stomach of other medication may be prolonged and data from this study will help assess the change in residence time in the presence of therapeutic doses of exenatide. this study will also evaluate the relationship between blood levels of exenatide and parameters measuring rate of stomach emptying.


Eligibility criteria:
inclusion criteria: * subjects with at least 1 year history of type 2 diabetes mellitus. * subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%. * between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive. exclusion criteria: * within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication. * persons who have previously completed or withdrawn from this study or any other study investigating exenatide. * subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics). * subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility. * subjects who have used insulin for more than 4 weeks within 3 months prior to screening. * blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.

Keywords: diabetes gastric emptying exenatide byetta amylin lilly
tranexamic acid in hip fracture surgery

Conditions: Hip Fracture

Summary: to determine if txa utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.


Eligibility criteria:
inclusion criteria: * acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging. * age 65 and older * low energy mechanism of injury * hip fracture fixation performed within 48 hours * english speaking * anticipated medical optimization for operative fixation * no other major trauma exclusion criteria: * retained hardware around the affected hip * infection around the affected hip * transfer patients with a length of stay \> 24 hours at the transferring hospital * diagnosis of deficient natural anticoagulation * known congenital thrombophilia (deficiency of protein c, s, antithrombin) * known allergy to txa * patients undergoing percutaneous pinning of the hip fracture
canadian ticagrelor survey

Conditions: Acute Coronary Syndrome

Summary: this study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in canada through a prescriber knowledge and understanding (kau) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and asa dosage.

effectiveness of risk minimisation interventions for ticagrelor in canada

Eligibility criteria:
inclusion criteria: - n/a (all prescribers will be contacted for participation) exclusion criteria: - participation in a previous wave of the survey.
novel blood test to predict safe foods for infants and toddlers with food protein-induced enterocolitis syndrome (fpies)

Conditions: Food Protein-Induced Enterocolitis Syndrome; Allergies; Pediatric Disorder

Summary: the aim of this study is to validate a blood test that can identify safe foods for food protein-induced enterocolitis syndrome (fpies). this study proposes a solution to the problems of fpies by developing a new blood assay that screens a large number of foods (more than 20) in a culture plate. if this blood test is successful it may be able to identify safe foods more quickly. the study will recruit 10 participants that will have more than 2 trigger foods.

participants will complete surveys and have blood draws during the study. additionally, participants will be asked to keep track of their diet as well as introduce safe foods identified by the researchers.

Eligibility criteria:
inclusion criteria: * diagnosis of fpies * have to have documented reactions to 2-3 trigger foods with recurrent delayed vomiting or documented reactions to 4 or more trigger foods with recurrent delayed vomiting. exclusion criteria: * patients who are currently on medications that suppress the immune system * patients who do not have at least 2 trigger foods identified. * patients who have a history of an organic gastrointestinal (gi) disease (e.g., inflammatory bowel disease, celiac disease, biliary disorders, bowel resection), cardiac, pulmonary, neurologic, renal, endocrine, or gynecological pathology * lack of parental or guardian informed consent.

Keywords: safe foods trigger foods vomiting
evaluation the effects of french maritime pine bark extract on the clinical status in traumatic brain injury patients

Conditions: Traumatic Brain Injury

Summary: introduction: traumatic brain injury (tbi) is one of the major health and socioeconomic problems in the world. immune-enhancing enteral formula has been proven to significantly reduce infection rate in tbi patient. one of the ingredients that can be used in immunonutrition formulas to reduce inflammation and oxidative stress is french maritime pine bark extract. objective: the main objective of present study is surveying the effect of french maritime pine bark extract on the clinical, nutritional and inflammatory status of tbi patients as the first human study in the world. method: this is double-blind, randomized controlled trial. block randomization are used. intervention group will receive french maritime pine bark extract supplement (oligopin) 150 mg for 10 days. control group will receive placebo for the same duration. inflammatory status (il-6, il- 1β, c-reactive protein) and oxidative stress status (malondialdehyde, total antioxidant capacity), at the base line, at the 5th day and at the end of the study (10th day) are measured. apache іі (acute physiologic and chronic health evaluation ii) for assessment of clinical status of patients and nutric questionnaires for assessment of nutritional status filled out at the base line, 5th day and the end of study. sofa (sequential organ failure assessment) questionnaire for assessment of organ failure filled out every other day. the mortality rate will be asked by phone within 28 days of the start of the intervention. weight, body mass index and body composition at baseline, 5th day and 10th day of intervention are measured. all analyses will be conducted by initially assigned study arm in an intention-to-treat analysis. the data will be expressed as mean ± sd.

randomization: investigators randomly assign eligible patients on enrolment (1:1) to either the control group or the intervention group. randomization is stratified by site and a randomization list of unique patient identifiers is generated by the study statistician using a computer-generated random block size. the classification is based on age (18 to 40 and 40 to 65 years old), gender (male / female) and apacheii score (0 to 35 and 35 to 71) using quadruple blocks.

Eligibility criteria:
inclusion criteria: * admission in icu due to tbi2 * 18 year ≤ age ≤ 65 year * gcs score ˃ 8 * stable hemodynamic and metabolic status in the first 24 to 48 hours * having enteral nutritional support * fill out the informed consent form by the patient or first-degree relatives of the patient exclusion criteria: * pregnancy and lactation * morbid obesity: bmi ≥ 40 * failure to start enteral nutrition in the first 24-48 hours * suffering from autoimmune disorders and hiv/aids * suffering or having history of cancer and any liver failure * receiving positive inotropic medications including dopamine, dobutamine and epinephrine * severe and active bleeding * suffering from sepsis * having history of known food allergies
early botox after spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the investigators would like to improve our understanding of how early intervention with the use of bladder chemodenervation can preserve bladder function in those with a new sci. although detrimental cystometric and tissue changes are known to occur, often within 3 months after sci, the investigators seek to document the time course of these changes and the range of severity of those changes in both those participants that receive prophylactic treatment and those who do not.


Eligibility criteria:
inclusion criteria: * male or female 18-65 years of age at time of sci. * english speaking * recent sci (within 20 weeks of injury). * documentation of a spinal cord injury at t6 or higher, american spinal injury association impairment scale (ais) level a or b as designated on initial (72 hour) ais exam. * ability for subject to comply with the requirements of the study. * written informed consent obtained from subject. exclusion criteria: * inability to return to research site (harborview medical center) for follow-up studies after initial hospitalization. * acute (as part of concurrent hospitalization) or history of bladder surgery (urethral or prostate surgery acceptable) or injury. * inability to provide informed consent. * pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * incarcerated in a detention facility or in police custody. * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. * active medical problems precluding the safe conduct of urodynamics, bladder chemodenervation, bladder biopsy (e.g., evidence of active bladder infection, ruled out by urine culture prior to procedures) * known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation * cardiovascular instability

Keywords: sci neurogenic bladder chemodenervation with bont-a botox autonomic dysreflexia
effectives of non-extraction orthodontic treatment of angle class i malocclusion

Conditions: Angle Class I

Summary: introduction: the investigators aimed to evaluate the effectiveness of non-extraction orthodontic treatment for angle class i malocclusion.

many people are also concerned about their oral health. when social communication is more important, aesthetic concerns also receive a lot of attention. a beautiful smile can boost self-assurance and empathy. angle class i malocclusion is prevalent, and dental malocclusion is a significant percentage of the population at all ages . tooth extraction is a controversial topic in orthodontics, with the general view being against it. angle and his students argued against it, but charles tweed saw recurrence in the 1930s after retreatment without extraction and retreatment with extraction. the use of tooth extraction therapy increased in the 1960s but has become less common since the late 20th century. the science of orthodontics has made significant advancements under the principle of least invasiveness, but the debate remains about whether to consider tooth extraction. the contemporary view believes that the majority of patients may and should be treated without tooth extraction, but in rare circumstances, extraction is necessary to make up for crowding and excessive incisor protrusion that harm the beauty. in truth, each individual must be thoroughly evaluated in light of their bite, cosmetic condition, and stability in the wake of therapy before any course of action is recommended. the investigators aimed to evaluate the effectiveness of non-extraction orthodontic treatment for angle class i malocclusion.

Eligibility criteria:
inclusion criteria: * patients (≥ 15 years) with indicated angle class i malocclusion and missing space ≤9mm * cervical vertebral maturation stages 5, 6, (cs5, cs6): cervical vertebrae 2, 3, and 4 have a concave curved lower border and have at least one rectangle c3, c4 cervical vertebra upright or at least square * no prior orthodontic treatment * fully erupted permanent teeth (except third molars) * voluntary research participation exclusion criteria: face soft tissue surgical procedures, periodontal disease, and maxillofacial congenital anomalies

Keywords: non-extraction orthodontics treatment angle class i malocclusion
oxidative stress in hypobaric hypoxia

Conditions: Hypobaric Hypoxia; Metabolomics; Oxidative Stress; Acute Mountain Sickness

Summary: the trial investigates changes in metabolism during high altitude expedition up to 6865m. a mass-spectrometry based platform is used to detect different oxidative stress related metabolites. symptoms of acute mountain sickness are evaluated and correlated with laboratory parameters.

background altitude related illness, which include acute mountain sickness (ams), high altitude pulmonary edema (hape) and high altitude cerebral edema (hace), is common in subjects exposed to high altitude during professional or leisure time activities. there are independent risk factors such as: individual susceptibility and rate of ascent. hape is a potentially life-threatening complication of high altitude stay, mostly occuring within the first 2-5 days of exposure. although there is a controversial discussion, excessive hypoxic pulmonary vasoconstriction is thought to be the main trigger for developing hape. beside the controversial discussion if hypobaric hypoxia leads to oxidative stress it is not known whether oxidative stress contributes to ams or hape. objective the investigators hypothesize that reactive oxygen species are generated during high altitude stay and contribute to the development of acute mountain sickness. furthermore they would like to describe other changes in metabolic pathways possibly contributing to vessel tone dysregulation. methods 36 healthy volunteers will examined during an high altitude medical research expedition to mount muztagh ata (7549m) in western china. acute mountain sickness scores and clinical parameters will be assessed. metabolomics analysis of more than 390 parameters, using a mass spectrometry-based targeted metabolomic platform, is used to detect systemic oxidative stress and functional impairment of enzymes that require oxidation-sensitive co-factors. furthermore routine laboratory test will be done, for example crp, creatinine and interleukines

Eligibility criteria:
inclusion criteria: * healthy * physical fit * mountaineering experience * 18-70 years exclusion criteria * any type of disease * regular intake of medicaments * history of high altitude pulmonary edema * severe acute mountain sickness below an altitude of 3500m * any history of high altitude cerebral edema

Keywords: high altitude hypobaric hypoxia metabolomics oxidative stress acute mountain sickness
quantifying the effect of the crane technique through three-dimensional imaging

Conditions: Pectus Excavatum; Funnel Chest

Summary: pectus excavatum is the most common congenital abnormality of the thoracic wall and occurs in 1 in 400 newborns. the gold standard treatment is the nuss bar procedure. however, in very severe cases, pectus exacavatum involves little or no space between the heart and sternum. because of the limited space, the nuss procedure is more difficult to perform and there is an increased risk of complications such as injuries to the heart or large vessels. however, this increased risk can again be reduced by using the crane technique. this technique increases the substernal space by sternal 'hoisting' via an external steel wire. despite the fact that this technique is commonly used, it is not known what its quantitative effect is on the substernal space during the nuss bar procedure. the subsequent aim of this study is to quantify the effect of the crane technique during minimally invasive repair of pectus excavatum through three-dimensional scans acquired before and after application of the crane technique.


Eligibility criteria:
inclusion criteria: * undergoing minimally invasive repair of pectus excavatum (through the nuss bar procedure) in conjunction with the crane technique. exclusion criteria: * none